Xanthine oxidase-IN-5

Cat. No.:	HY-144456
CAS No.:	2276711-87-4
Molecular Formula:	$C_{18}H_{16}FN_3O_3$
Molecular Weight:	341.34
Target:	Xanthine Oxidase
Pathway:	Metabolic Enzyme/Protease
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	Xanthine oxidase-IN-5 is an effective and orally active xanthine oxidase (XO) inhibitor with IC_{50} value of 0.70 μM. Xanthine oxidase-IN-5 displays favorable agent-like properties with ligand efficiency (LE) and lipophilic ligand efficiency (LLE) values of 0.33 and 3.41, respectively. Xanthine oxidase-IN-5 shows potent hypouricemic effects in hyperuricemic rat model[1].
IC_{50} & Target	IC_{50}: 0.70 μM (XO)[1]
In Vivo	Xanthine oxidase-IN-5 (compound 9m) shows potent hypouricemic effects at an oral dose of 20 mg/kg in a rat hyperuricemia model induced by potassium oxonate[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Potassium oxonate-induced hyperuricemic rat model[1]
Dosage:	20 mg/kg
Administration:	PO; single (measured serum uric acid after 0.5 - 8 hours)
Result:	Showed potent hypouricemic effects at an oral dose of 20 mg/kg in a rat hyperuricemia model induced by potassium oxonate.

REFERENCES

[1]. Zhang TJ, Zhang Y, Zhang ZH, et al. Discovery of 4-(phenoxymethyl)-1H-1,2,3-triazole derivatives as novel xanthine oxidase inhibitors. Bioorg Med Chem Lett. 2022;60:128582.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA